How did Otsuka’s centanafadine perform in its Phase 3b ADHD trial?

Otsuka’s centanafadine met its main goal in a Phase 3b study of 315 adults with ADHD and comorbid anxiety, showing an 18.5‑point symptom reduction versus 12.6 for placebo. The drug also improved anxiety scores and reinforced a potential FDA approval decision expected by July 24, positioning Otsuka for a possible launch pending DEA review.